MARKET

RCEL

RCEL

Avita Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.07
+0.45
+1.99%
Closed 16:00 08/05 EDT
OPEN
22.95
PREV CLOSE
22.62
HIGH
23.33
LOW
22.76
VOLUME
1
TURNOVER
--
52 WEEK HIGH
55.35
52 WEEK LOW
20.00
MARKET CAP
488.50M
P/E (TTM)
-58.4939
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RCEL stock price target is 47.75 with a high estimate of 60.00 and a low estimate of 41.00.

EPS

RCEL News

More
AVITA Therapeutics to Participate at the Canaccord Genuity 40th Annual Growth Conference
AVITA Therapeutics, Inc. (NASDAQ: RCEL) (ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management wil
Business Wire · 07/29 20:01
BARDA to launch procurement of Avita Recell System
Seeking Alpha - Article · 07/13 15:21
BARDA To Initiate Procurement Of The RECELL System For Emergency Response Preparedness
AVITA Therapeutics, Inc. (NASDAQ:RCEL, ASX:AVH)))), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet
Benzinga · 07/13 12:08
AVITA Therapeutics sees FY 2020 revenue as high as $14.3M
Seeking Alpha - Article · 07/09 13:55
AVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020
Business Wire · 07/09 13:00
AVITA Therapeutics Sees Prelim. Q4 RECELL System Sales $3.79M, Total Net Revenue $3.88M
Preliminary Unaudited Results for Three Month Period Ended June 30, 2020 With effect from July 1, 2020, the Company is reporting financial results in United States dollars (US$), and prepared in accordance with U.S.
Benzinga · 07/09 12:09
What Type Of Shareholders Own The Most Number of AVITA Therapeutics, Inc. (ASX:AVH) Shares?
Simply Wall St. · 07/08 22:34
AVITA Medical Limited Implementation of the Scheme of Arrangement to Redomicile from Australia to the United States of America
Business Wire · 06/29 05:31

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About RCEL

AVITA Therapeutics, Inc., formerly Avita Medical Limited, is a regenerative medicine company with a technology platform to address medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. Its technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. Its product, the RECELL System for the treatment of acute thermal burn injuries in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a way to treat severe burns that significantly reduces the amount of donor skin required. It is designed to be used at the point of care alone or in combination with split-thickness skin autografts depending on the depth of the burn injury.
More

Webull offers kinds of Avita Therapeutics Inc stock information, including NASDAQ:RCEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCEL stock methods without spending real money on the virtual paper trading platform.